JP2005507927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507927A5 JP2005507927A5 JP2003539606A JP2003539606A JP2005507927A5 JP 2005507927 A5 JP2005507927 A5 JP 2005507927A5 JP 2003539606 A JP2003539606 A JP 2003539606A JP 2003539606 A JP2003539606 A JP 2003539606A JP 2005507927 A5 JP2005507927 A5 JP 2005507927A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- expression
- vector according
- cell
- vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013604 expression vector Substances 0.000 claims 77
- 101150026563 NR4A2 gene Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 210000002569 neuron Anatomy 0.000 claims 8
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 241000702421 Dependoparvovirus Species 0.000 claims 5
- 210000004002 dopaminergic cell Anatomy 0.000 claims 5
- 230000001537 neural effect Effects 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 230000003291 dopaminomimetic effect Effects 0.000 claims 3
- 210000003523 substantia nigra Anatomy 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34100901P | 2001-10-30 | 2001-10-30 | |
| PCT/US2002/034613 WO2003037260A2 (en) | 2001-10-30 | 2002-10-30 | Methods and compositions for treating parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507927A JP2005507927A (ja) | 2005-03-24 |
| JP2005507927A5 true JP2005507927A5 (enExample) | 2006-01-05 |
Family
ID=23335891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003539606A Pending JP2005507927A (ja) | 2001-10-30 | 2002-10-30 | パーキンソン病を処置するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050070493A1 (enExample) |
| EP (1) | EP1469730A4 (enExample) |
| JP (1) | JP2005507927A (enExample) |
| CA (1) | CA2464887A1 (enExample) |
| WO (1) | WO2003037260A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005075990A2 (en) * | 2004-02-07 | 2005-08-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2) |
| CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| KR20210131991A (ko) | 2018-11-14 | 2021-11-03 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 구획-특이적 카고 전달을 위한 조성물 및 방법 |
| EP3880179A2 (en) * | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| US20220226269A1 (en) * | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| JP2024532963A (ja) | 2021-04-08 | 2024-09-11 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８特異的抗体コンストラクト及びその組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5869337A (en) * | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) * | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5589362A (en) * | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
| US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| EP0705334A1 (en) * | 1993-06-14 | 1996-04-10 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| JPH10501686A (ja) * | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのｄｎａのａａｖ仲介送達 |
| CA2329259C (en) * | 1998-05-27 | 2003-08-05 | Avigen, Inc. | Convection-enhanced delivery of aav vectors |
| US6284539B1 (en) * | 1998-10-09 | 2001-09-04 | Neuralstem Biopharmaceuticals, Ltd. | Method for generating dopaminergic cells derived from neural precursors |
| US6312949B1 (en) * | 1999-03-26 | 2001-11-06 | The Salk Institute For Biological Studies | Regulation of tyrosine hydroxylase expression |
| DK1173548T3 (da) * | 1999-05-03 | 2007-10-08 | Neuro Therapeutics Ab | Materialer og fremgangsmåder til frembringelse af dopaminerge neuroner |
| WO2003012040A2 (en) * | 2001-07-27 | 2003-02-13 | Baylor College Of Medecine | Mutant nurr1 gene in parkinson's disease |
-
2002
- 2002-10-30 JP JP2003539606A patent/JP2005507927A/ja active Pending
- 2002-10-30 WO PCT/US2002/034613 patent/WO2003037260A2/en not_active Ceased
- 2002-10-30 CA CA002464887A patent/CA2464887A1/en not_active Abandoned
- 2002-10-30 EP EP02778672A patent/EP1469730A4/en not_active Withdrawn
-
2004
- 2004-04-30 US US10/837,182 patent/US20050070493A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI848486B (zh) | 組織選擇性轉基因表現 | |
| US12146150B2 (en) | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery | |
| Gardiner et al. | AAV mediated expression of anti-sense neuropeptide Y cRNA in the arcuate nucleus of rats results in decreased weight gain and food intake | |
| JP2005512515A5 (enExample) | ||
| CN107530451A (zh) | 用于天使人综合征的基因治疗方法的修饰的ube3a基因 | |
| AU2008316398A1 (en) | Splice variants of GDNF and uses thereof | |
| Woodbury et al. | Novel structure of the human GDNF gene | |
| KR20230123925A (ko) | Neurod1 및 dlx2 벡터 | |
| WO2025209599A1 (zh) | 新型光敏感通道蛋白vr2.0及其用途 | |
| CN109971729A (zh) | 一种新型酶组合物 | |
| JP2023526449A5 (enExample) | ||
| JP2023540130A5 (enExample) | ||
| TW202539725A (zh) | 用於抑制α-突觸核蛋白(SYNUCLEIN)表現之鋅指蛋白轉錄因子 | |
| JP2022552003A5 (enExample) | ||
| EP3516052B1 (en) | Recombinant dgkk gene for fragile x syndrome gene therapy | |
| US20050070493A1 (en) | Methods and compositions for treating Parkinson's disease | |
| CN119351409A (zh) | 优化的编码脑源性神经营养因子的多核苷酸及其应用 | |
| Rahman et al. | Optogenetics of the spinal cord: use of channelrhodopsin proteins for interrogation of spinal cord circuits | |
| TW202229320A (zh) | 用於抑制α-突觸核蛋白(SYNUCLEIN)表現之新穎鋅指蛋白轉錄因子 | |
| WO2007122976A1 (ja) | ポリグルタミン病の治療剤又は発病抑制剤 | |
| Verhaagen et al. | Gene therapy for spinal cord injury | |
| Baez et al. | Using Herpes Simplex Virus Type 1-Based Amplicon Vectors for Neuroscience Research and Gene Therapy of Neurologic Diseases | |
| WO2025217927A1 (zh) | 一种治疗帕金森综合征的药物组合物 | |
| CN116710566A (zh) | Neurod1载体 | |
| CN116782921A (zh) | Neurod1组合载体 |